CREATV BIO AND NEOVIA ONCOLOGY ANNOUNCE STRATEGIC PARTNERSHIP TO STUDY MULTIPLE DRUG RESISTANCE (MDR) IN SOLID TUMORS
Summary
Creatv Bio and Neovia Oncology have formed a strategic partnership to study multiple drug resistance in advanced solid tumors. The collaboration will use Creatv Bio’s liquid biopsy capabilities to generate translational and biomarker data for Neovia’s clinical studies. The companies want to improve patient stratification and better understand treatment response in late-line therapy. Neovia is also exploring broader applications for its NEV-801 program in next-generation oncology settings, including ADC strategies.
Classifications
industries
No industries detected
applications
Accounting and Taxes
AskAI Classifications
Labels
SaaS
Media Intelligence Software
Marketing Technology
Linked Companies
Cision Ltd.
$500M to $1B